Please Wait...

Imaging Modalities

Medical and Diagnostic Imaging Modalities

Bioclinica has extensive experience with medical imaging and diagnostic imaging modalities for clinical trials.

CT

  • Angiography (CTA)
  • Lung Density/Volume
  • Quantitative Computed Tomography (QCT)

DXA

  • Bone Mineral Density (BMD)
  • Body Composition
  • Hip Structural Analysis (HSA)

MRI

  • Angiography (MRA)
  • Body and Neuro
  • Cardiac MRI
  • Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI)

Nuclear Medicine

  • Planar
  • Multi-Gated Acquisition Scan (MUGA)
  • Single Photon Emission Computed Tomography (SPECT)
  • Whole Body
  • PET
  • PET/CT

OCT

  • Retinal thickness and volume
  • Retinal Nerve Fiber layer (RNFL) thickness
  • Macular holes and puckers

Ultrasound

  • Abdominal/small parts Ultrasound
  • Echocardiography
  • FMD (flow mediated dilation)
  • Duplex
  • Duplex Doppler
  • CEUS (Contrast Enhanced Ultrasound)
  • B-Mode and M-Mode

X-Ray

  • General
  • Angiography
  • Mammography

Want to learn more about how Bioclinica’s medical and diagnostic imaging modalities solutions can benefit your clinical studies? Request a demo today!

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Great advice from our Dir. Cardiovascular Imaging on how to achieve top quality imaging acquisitions & assessments… https://t.co/P57970FrOf
bioclinica (16 hours ago)
RT @CenterWatch: #CWWeekly: The increasing trend of adopting digital health and #mhealth apps for patient care. Read more, https://t.co/wo9…
bioclinica (17 hours ago)
RT @CenterWatch: Examining the difference between #patient engagement & patient recruitment. Read more in #CWPulse by @AshleyTointon, https…
bioclinica (17 hours ago)
RT @CenterWatch: How can #socialmedia play a role in health disparities and #clinicaltrial patient recruitment? Read more in #CWPulse by @A…
bioclinica (17 hours ago)
RT @RAPSorg: What New @FDAcdrhIndustry Guidance is Coming in FY 2018: Alternative 510(k) Pathway and More | #Regulatory Recon https://t.co/…
bioclinica (17 hours ago)
RT @RAPSorg: .@US_FDA Finalizes Guidance on Promotional Drug Labeling and Ads | #Regulatory Focus https://t.co/2rmtTWajlf #FDA #pharma
bioclinica (17 hours ago)

Latest Blogs:

Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen
Congressman Meehan and Bioclinica CEO John Hubbard at recent visit to Bioclinica's Audubon offices